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 ABSTRACT  
Background/aim: Deficiency of acetyl-L-carnitine (ALC) and L-carnitine (LC) appears to play a 
role in peripheral diabetic neuropathy, although the evidence in humans is still limited. We 
conducted a systematic review and meta-analysis investigating the effect of ALC on pain and 
electromyographic parameters in people with diabetic neuropathy.  
Methods: A literature search in major databases, without language restriction, was undertaken. 
Eligible studies were randomized controlled trials (RCTs) or pre and post-test studies. The effect of 
ALC supplementation on pain perception and electromyographic parameters in patients with 
diabetic neuropathy was compared vs. a control group (RCTs). The effect of ALC/LC on 
electromyographic parameters were also calculated vs. baseline values. Standardized mean 
differences (SMD) and 95% confidence intervals (CIs) were used for summarizing outcomes.  
Results: Six articles, with a total of 711 diabetic participants, were included. Three RCTs (340 
treated with ALC vs. 203 placebo and 115 with methylcobalamine) showed that ALC reduces pain 
perception (SMD=-0.45; 95%CI: -0.86 to -0.04; p=0.03; I2=85%). Compared to controls, ALC 
supplementation improved nerve conduction velocity and amplitude response for ulnar nerve (both 
sensory and motor component). Compared to baseline values, ALC/LC supplementation improved 
nerve conduction velocity for all the sensory and motor nerves (except ulnar and peroneal) 
investigated and the amplitude of all nerves. The onset of adverse events was generally limited to 
minor side effects.  
Conclusion: ALC appears to be effective in reducing pain due to diabetic neuropathy compared to 
active or placebo controls and improving electromyographic parameters in these patients. 
 
Keywords: acetyl-L-carnitine; neuropathy; diabetes; meta-analysis.   
INTRODUCTION 
Peripheral neuropathy is one of the most prevalent complications of diabetes mellitus, with  
prevalence estimates ranging from 12 to 50%.[1] The most common form of peripheral neuropathy 
in diabetes is the distal symmetric polyneuropathy, a form affecting both sensory and motor nerves. 
[1]  
The complications due to diabetic neuropathy are multiple (e.g. asthenia, paresthesia in initial stages 
and in advanced ones ulcers and deformation of lower extremities) and often associated with higher 
presence of disability and poor quality of life. [2] These effects are mainly due to the presence of 
pain, one of the most common symptoms associated with diabetic neuropathy.[1]  
The management of symptomatic diabetic sensory neuropathy presents a therapeutic challenge for 
the physicians, since the therapies for this conditions are predominantly limited to seeking to obtain 
good glucose control and the use of analgesic medications.[3,4] Such interventions are often not 
effective in symptoms and do not address the pathogenesis of diabetic neuropathy. Although the 
pathogenesis of this condition is not completely understood, one of the main mechanisms 
responsible seems to be the reduced availability of acetyl groups, necessary for the synthesis of 
choline.[5] A deficiency of acetyl-L-carnitine (ALC) and L-carnitine (LC) seems to play a pivotal 
role in this pathway[6], since a deficit of ALC has been shown to cause damage to the myelin 
sheath.[7] In animal models, the exogenous administration of ALC increases artemin levels and 
enhances the expression of nerve growth factor (NGF)[8,9], enhances antioxidant activity[10] and 
microvascular protein permeability[11], and induces long-term upregulation of the presynaptic 
mGlu2 receptors [12]; in this way, ALC supplementation induces neuroprotective, neurotrophic and 
analgesic effects in the peripheral nervous system. [12,13] 
Regarding human beings, ALC is recommended in the tier 1 of neuropathic pain treatments by the 
Mayo Clinic proceedings [14], and a recent meta-analysis has confirmed that administration of ALC 
was able to improve pain perception in people affected by peripheral neuropathy.[15] Although this 
work advanced our knowledge regarding this important topic, a number of  limitations persist, for 
instance, the authors considered all kinds of neuropathies together (although they have different 
pathogeneses) and they did not investigate the effect of ALC on electromyographic parameters, the 
most common method for diagnosis and evaluating peripheral neuropathy.[1] 
Given the mentioned limitations in the literature, we aimed to investigate the effect of ALC on pain 
and electromyographic parameters in diabetic neuropathy. We hypothesized that ALC 
supplementation is beneficial for symptomatology and electromyographic features of diabetic 
neuropathy.  
  
  
METHODS 
This systematic review adhered to the PRISMA[16] and MOOSE[17] statements and followed a 
structured, but unpublished protocol. 
 
Data sources and literature search strategy 
Two investigators (NV and GS) independently conducted a literature search using PubMed, 
EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov without 
language restriction, from database inception until 05 June 2016 for randomized controlled trials 
(RCTs) and descriptive studies (i.e. without a control group) investigating the effect of ALC 
supplementation in patients with diabetic neuropathy.  
In PubMed, the following search strategy was used: “(carnitine [Text word] OR "Carnitine"[Mesh]) 
AND (diabet*) AND (neurop*)”. Conference abstracts and reference lists of included articles were 
hand-searched to identify and potential additional relevant articles. Any inconsistencies were 
resolved by consensus with a third author (SM). 
 
Study selection  
Inclusion criteria for this meta-analysis were: i) RCTs or pre or posttest studies;  ii) included 
diabetic participants with peripheral neuropathy diagnosed through electromyography (EMG); iii) 
investigated the use of carnitine supplementation (regardless of administration route); iv) included 
data regarding pain (due to neuropathy) and/or regarding EMG parameters.  
Studies were excluded if: i) did not include humans; ii) investigated the effect of carnitine on other 
causes of neuropathic pain (e.g. due to chemotherapy); iii) included participants with diabetes, but 
without a neuropathy.  
 
  
 
Data extraction  
Two independent investigators (NV and BS) extracted key data from the included articles in a 
standardized Excel sheet. A third independent investigator (GS) checked the extracted data.  
For each article, we extracted data about authors, year of publication, country, study design 
(RCT/descriptive), medications used for the treatment of diabetes, daily ALC/LC dosage, follow-up 
duration (in weeks) and mean age (by treatment type: ALC or control group). Finally, we extracted 
data regarding the adverse events reported in each study.  
 
Outcomes 
The primary outcome was the change of pain perception at follow-up assessed through a validated 
scale (e.g. Visual Analogue Scale) between participants treated with ALC vs. controls.  
As secondary outcomes, we considered EMG parameters in terms of conduction velocity and 
response amplitude in terms of: 1) differences between follow-up and baseline (pre and post 
treatment) in ALC vs. controls and 2) within patients treated comparing the data at follow-up vs. 
baseline in people treated with ALC/LC.     
 
Assessment of study quality 
Two authors (NV, GS) completed scoring using the Jadad’s scale[18] for assessing the quality and 
the risk of bias of the RCTs included. This quantifies the trial quality based on the description and 
appropriateness of randomization (2 points), blinding procedures (2 points),and description of 
withdrawals (1 point). A value less than 3 (over a maximum of 5) usually indicates a low-quality 
study at high risk of bias.[19] 
 
Data synthesis and statistical analysis  
All analyses were performed using Comprehensive Meta-Analysis (CMA) 3 and Revman 5.3. 
Outcomes with at least two studies were meta-analyzed, and in cases with less we described the 
data in a descriptive summary. When multiple assessments were made, the longest follow-up time 
was included in our analyses.  
The primary analysis compared the values of pain scales between participants treated with ALC 
supplementation vs. controls. We calculated the difference between the means of the treatment and 
placebo groups using the follow-up data through standardized mean differences (SMD) with their 
95% confidence intervals (CIs), applying a random-effect model.[20]  
For the secondary analysis, a similar analysis was made for ALC, whilst for ALC/LC this analysis 
for EMG parameters was limited to the differences between follow-up and baseline values (pre and 
post treatment). Both RCTs and descriptive studies reporting quantitative data on EMG were used.   
Heterogeneity across studies was assessed by the I2 metric and chi square statistics. Given 
significant heterogeneity (I2 >50%, p<0.05) and for outcomes having at least 5 studies, we planned 
to run a meta-regression analysis. No sufficient number of studies was reached by any outcome 
included.   
Publication bias was assessed by a visual inspection of funnel plots and calculating the Egger bias 
test.[21] Then, to account for publication bias, we used the trim-and-fill method, based on the 
assumption that the effect sizes of all the studies are normally distributed around the center of a 
funnel plot; in the event of asymmetries, the test adjusts for the potential effect of unpublished 
studies.[21]  For all analyses, a p-value less than 0.05 was considered statistically significant.   
RESULTS 
Search results 
Altogether, the searches yielded 230 non-duplicated articles. After excluding 218 articles based on 
title/abstract review (predominantly because they did not include participants with diabetic 
neuropathy), 12 articles were retrieved for full text review. Finally, six articles[22–27] were 
included in the qualitative synthesis and five [23–27] were included in the quantitative analysis.  Of 
the included articles, three were RCTs [23–25] (Figure 1).  
 
Study and patient characteristics 
Full descriptive details of the included studies are reported in Supplementary Table 1 (ALC-
RCTs) and Supplementary Table 2 (LC-descriptive studies). All the studies together included a 
total of 711 diabetic participants with peripheral neuropathy.  
The three RCTs[23–25] included in our meta-analysis included a total of 658 diabetic participants 
with neuropathy. Across the 3 RCTs, 340 were treated with ALC (mean age=57.8 years), whilst the 
318 controls (mean age=57.8 years) were treated with placebo (n=203) or methylcobalamine 
(n=115), as reported in the Supplementary Table 1. All the three studies included both type 1 and 
2 diabetes with a concomitant treatment with oral antidiabetic agents and insulin.. The median 
follow-up period was 48 weeks (range: 24-52). The quality, assessed through the Jadad’s scale[18], 
indicates a low risk of bias.  
The other three descriptive studies[22,26,27] reporting data regarding the effect of LC on diabetic 
neuropathy are described in the Supplementary Table 2. All three descriptive studies were 
conducted in Turkey and involved 53 people with type 1 and/or 2 diabetes. The median follow-up 
period for these studies was 8 weeks (range: 2-40). 
 
 
 
Meta-analysis of the effect of ALC on pain 
Figure 2 shows the effect of ALC on pain in people with diabetic neuropathy. Two studies[23,25] 
reported the pain perception using a Visual Analogue Scale, whilst another RCT [24] used the 
neuropathy symptom score. Overall, ALC significantly reduced pain perception in 340 participants 
vs. 318 controls (203 treated with placebo and 115 with methylcobalamine) (4 cohorts in 3 RCTs 
[23–25]; SMD=-0.45; 95%CI: -0.86 to -0.04; p=0.03; I2=85%).  
Although the data were heterogeneous, a meta-regression analysis was not possible due to the 
limited number of the studies available, whilst the evidence of the publication bias was low (Egger 
bias test=0.78; p=0.48).  
 
Meta-analysis of the effect of ALC and ALC/LC on electromyographic parameters 
All studies (except one[22]) reported the effect of ALC/LC on EMG parameters. We were able to 
meta-analyze pre and post-test changes from 4 of the 5 studies reporting data on EMG parameters.  
One study[25] reported the data only as descriptive findings.  
Table 1 shows the meta-analysis of EMG parameters between patients treated with ALC vs. 
controls in two studies.[23,24] Compared to controls, the treatment with ALC improved the nerve 
conduction velocity a both sensory (SMD=0.60; 95%CI: 0.35-0.86, p<0.0001; I2=94%) and motor 
(SMD=0.67; 95%CI: 0.43-0.91, p<0.0001; I2=0%) ulnar nerve. We observed a similar improvement 
for both sensory and motor component for ulnar nerve, taking response amplitude as outcome. ALC 
improved also the response amplitude for motor nerve median as reported in Table 1. Except few 
exceptions, the heterogeneity was high. The publication bias analysis was not feasible due to the 
limited number of studies available for each outcomes. 
Table 2 shows the meta-analysis of EMG parameters calculated as the difference between follow-
up and baseline values after ALC/LC treatment. Regarding nerve conduction velocity, ALC/LC 
significantly improved all the three sensory nerves investigated with a SMD ranging from 0.76 
(95%CI: 0.50-1.02; 3 studies; 122 participants) for median nerve to 1.01 m/s (95%CI: 0.74-1.29; 3 
studies; 118 participants) for sural nerve. A similar finding was evident for median (SMD=0.54 
m/s; 95%CI: 0.25-0.83; 4 studies; 124 participants) and tibial motor nerve (SMD=0.49 m/s; 95%CI: 
0.18-0.79; 3 studies; 86 participants) (Table 2, upper part).   
For all these results, the heterogeneity was low (as shown by the I2<50%) and publication bias was 
unlikely, except for ulnar motor nerve for which, however, the trim and fill procedure did not 
change our results.  
The effect of ALC/LC on response amplitude seems to be comparable to the effect of nerve 
conduction velocity. ALC/LC were able to improve the response amplitude for all sensory nerves 
(with a SMD ranging from 0.79 for sural to 1.04 uV for median nerve) and for all motor nerves 
(SMD from 0.60 for peroneal to 0.74 mV for tibial), except for median nerve. However, after 
trimming one study at the left of the mean, also this finding becomes statistically significant 
(SMD=1.46 mV; 95%CI: 0.24-2.69) (Table 2, lower part).  
Contrary to the findings observed for conduction velocity, the heterogeneity for response amplitude 
was generally high (I2> 70%) for all the outcomes included.  
Finally, Sima et al. in their trial[25] reported a not significant effect of ALC on EMG parameters, 
when compared to placebo, but the data after/before ALC supplementation were not available. 
Anyway, the trial [25] showed significant improvements in sural nerve fiber numbers and 
regenerating nerve fiber clusters, and vibration perception was improved. 
 
Meta-regression analysis 
Although some outcomes suffered of high heterogeneity (as indicated by an I2>50%), the number of 
the studies for each outcome was too low for doing a reliable meta-regression analysis.  
 
 
 
 
Adverse events 
As showed in the Supplementary Table 3, no severe side effects (e.g. death, onset of 
cardiovascular diseases) emerged after treatment with ALC/LC in RCTs and in one study [25] some 
neurological signs (pain, hyperesthesia and paraesthesia) were more frequent in placebo group than 
ALC. All the studies, however, reported that people treated with ALC/LC experienced some 
gastrointestinal side effects of minor entity, like vomiting or nausea.   
 
 
  
DISCUSSION 
In this systematic review and meta-analysis including for pain  three RCTs and three observational 
studies and for EMG two studies for a total of 711 diabetic participants, we showed that ALC could 
have a beneficial effect on pain and electromyographic parameters in diabetic people with 
peripheral neuropathy compared to controls, whilst the treatment with ALC/LC was able to improve 
EMG parameters compared to baseline.  
Compared to the control group, ALC was associated with a significant reduction in pain perception 
in people affected by diabetic neuropathy. The mechanism leading to this analgesic effect seems to 
be related to the acetylation and the activation of the transcription of NF-kB, promoted by ALC, 
acting as a donor of acetyl groups. [12,28] This activation corresponds to an increase in the 
expression of mGlu-2 receptor that link glutamate in the synapses of the dorsal horn with a 
consequent reduction in pain hypersensitivity. [12,28] As  previously reported in the meta-analysis 
of Li et al.[15] the effect of ALC on neuropathic pain was stronger in diabetes than other 
conditions. One hypothesis is that in diabetes, the effect of glutamate is more pronounced than other 
neuropathies[29,30] and consequently ALC works better in this condition.  
The descriptive studies reported that LC is able to improve EMG parameters, confirming that, 
beyond the activity of ALC as a donor of acetyl groups, carnitine supplementation anyway presents 
a neurotrophic effect. The reasons of why some nerves have and other have not a beneficial effect 
from LC is not known and further research is needed to disentangle this issue. 
In our meta-analysis, ALC/LC were also able to significantly improve the nerve conduction velocity 
and the amplitude of several upper and lower limbs nerves. In EMG, latency is the time needed for 
the stimulus to initiate an evoked potential: this parameter reflects the conduction along the fastest 
fibers. Peak latency is the latency along the majority of axons and is measured at the peak 
amplitude. Both these parameters are affected by the state of the myelination of the nerve.[31] 
Reduction of amplitudes of recorded responses generally indicates a loss of axons.[31] The 
conduction velocity also depends on the state of myelination and is often decreased in disorders 
affecting nerve myelination, although it could be normal if a few myelinated axons remain 
intact.[31] From a molecular point of view, ALC seems to able to enhance the expression of NGF 
and its receptors,  increases the regeneration of the nerve reducing the myelinic degeneration and 
finally improves the anatomy and physiology of the nerve.[8,14,32] All these factors probably 
contributed to the effect of ALC on EMG parameters.  
The benefits of ALC treatment in diabetic patient are amplified by the fact there are to date very 
few adverse events reported in the literature. All the three RCTs[23–25], in fact, reported a similar 
frequency of side effects among people treated with ALC and controls, whilst the only descriptive 
study[26] reporting adverse events showed that only 2 patients were affected by an adverse effect 
and they did not discontinue the treatment with this supplement.  
The findings of our work should be interpreted within its limitations. First, the findings of EMG 
between treated and control group were substantially limited only to two studies. Thus, we were not 
able to run a reliable meta-regression analysis to verify if the improvement in the EMG parameters 
was associated with decrease in pain. Other trials are needed to disentangle this issue. Second, most 
of all the amplitude parameters and the primary outcome suffered from high heterogeneity, and we 
were not able the address this heterogeneity. Finally, the length of follow-up of all the studies 
included was relatively short and future studies with a longer follow-up period are needed. 
Similarly, the mean dosage of ALC/LC was highly variable among the studies. Among the 
strengths of our work we can consider that is the first meta-analysis investigating the effect of ALC 
on pain and EMG parameters on diabetic neuropathy. Moreover, our review suggests that ALC 
treatment is well-tolerated in diabetic patients.  
In conclusion, our work suggests that ALC may be effective in reducing pain due to diabetic 
neuropathy compared to active or placebo controls. Moreover, ALC seems to improve some EMG 
parameters for both sensory and motor nerves compared to controls and similarly to LC compared 
to baseline estimates. Future RCTs are needed confirm our findings, particularly regarding the 
EMG parameters compared to placebo.   
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FIGURE LEGENDS 
Figure 1. PRISMA flow-chart 
 
 
 
 
 
 
 
Figure 2. Effect of acetyl-L-carnitine (ALC) on neuropathic pain in randomized controlled 
trials.  
 
 
 
Abbreviations: CI: confidence intervals; IV: inverse variance; SD: standard deviations. 
 
